Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

7.235 +0.255 (+3.65%)
Streaming Delayed Price Updated: 3:21 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Reports Third Quarter 2025 Financial Results
From Evolus
Via Business Wire
News headline image
Evolus to Participate in 2025 Stifel Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus to Report Third Quarter Financial Results on November 5, 2025
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
From Evolus
Via Business Wire
News headline image
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
From Evolus
Via Business Wire
News headline image
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Evolus
Via Business Wire
News headline image
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins
From Evolus
Via Business Wire
News headline image
Evolus to Report Second Quarter Financial Results on August 5, 2025
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolysse™ Recognized in 2025 Shape Skin Awards
From Evolus
Via Business Wire
News headline image
Evolus Announces Departure of its Chief Financial Officer
From Evolus
Via Business Wire
News headline image
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Reports First Quarter 2025 Results
From Evolus
Via Business Wire
News headline image
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
From Evolus
Via Business Wire
News headline image
Evolus to Report First Quarter Financial Results on May 7, 2025
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Announces Commercial Launch of Evolysse™
From Evolus
Via Business Wire
News headline image
Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
From Evolus
Via Business Wire
News headline image
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
From Evolus
Via Business Wire
News headline image
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
From Evolus
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.